Abivax Announces Availability of Documents for Upcoming General Meeting

Abivax SA, a clinical-stage biotechnology company listed on Euronext Paris and Nasdaq, has officially announced that its upcoming ordinary and extraordinary general meeting is scheduled for May 30, 2024, at 10:00 am CEST. The meeting will take place at the Dechert (Paris) LLP offices on rue Bayard, Paris. Ahead of the general meeting, the company has made all crucial preparatory documents available for shareholder review.

The essential documents, including the preliminary notice of the meeting with the agenda and draft resolutions, have been published in the Bulletin des Annonces Légales Obligatoires on April 24, 2024. Shareholders wishing to obtain these materials via postal or electronic means can request until May 25, 2024. Additionally, bearer shareholders are required to provide a registration certificate from their securities account.